Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$0.52 -8.7%	$0.50	$0.40 ▼ $3.02	$30.30M	1.13	520,729 shs	415,913 shs
ANVS Annovis Bio	$2.51 -8.1%	$2.64	$1.11 ▼ $10.54	$53.20M	1.51	324,064 shs	349,630 shs
MDWD MediWound	$18.53 -0.6%	$20.22	$14.14 ▼ $22.50	$201.46M	0.32	55,999 shs	53,903 shs
RAPT Rapt Therapeutics	$10.49 -2.9%	$9.23	$5.67 ▼ $26.56	$178.59M	0.01	98,493 shs	31,794 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	-8.70%	-1.54%	+16.43%	-2.78%	-89.21%
ANVS Annovis Bio	-7.55%	-13.89%	+5.46%	+55.42%	-73.10%
MDWD MediWound	-0.59%	-8.85%	-3.09%	+7.42%	-3.64%
RAPT Rapt Therapeutics	-2.87%	-21.19%	+30.96%	+35.63%	-58.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALXO ALX Oncology	3.254 of 5 stars	3.4	3.0	0.0	1.1	4.2	1.3
ANVS Annovis Bio	2.008 of 5 stars	3.5	1.0	0.0	2.0	1.7	0.6
MDWD MediWound	1.9355 of 5 stars	3.5	2.0	0.0	0.0	0.8	0.6
RAPT Rapt Therapeutics	4.1023 of 5 stars	3.3	1.0	4.2	3.6	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALXO ALX Oncology	2.83	Moderate Buy	$3.30	536.94% Upside
ANVS Annovis Bio	3.00	Buy	$18.00	617.13% Upside
MDWD MediWound	3.00	Buy	$32.25	74.04% Upside
RAPT Rapt Therapeutics	2.57	Moderate Buy	$20.57	96.11% Upside

Current Analyst Ratings Breakdown

Latest ANVS, ALXO, RAPT, and MDWD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2025	RAPT Rapt Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral	$14.00
7/22/2025	RAPT Rapt Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$31.00
7/10/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00
6/9/2025	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $12.00
6/2/2025	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$34.00
5/22/2025	MDWD MediWound	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$25.00 ➝ $31.00
5/22/2025	RAPT Rapt Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $8.00
5/22/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$48.00
5/21/2025	ALXO ALX Oncology	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1.20 ➝ $1.00
5/15/2025	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $17.00
5/9/2025	ALXO ALX Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $2.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$2.14 per share	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.67 per share	N/A
MDWD MediWound	$19.21M	10.42	N/A	N/A	$2.89 per share	6.41
RAPT Rapt Therapeutics	$1.53M	113.40	N/A	N/A	$11.51 per share	0.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALXO ALX Oncology	-$134.85M	-$2.47	N/A	N/A	N/A	N/A	-104.43%	-77.74%	8/14/2025 (Estimated)
ANVS Annovis Bio	-$24.59M	-$2.16	N/A	N/A	N/A	N/A	-300.56%	-193.50%	8/13/2025 (Estimated)
MDWD MediWound	-$30.22M	-$2.09	N/A	N/A	N/A	-110.45%	-74.12%	-30.92%	8/13/2025 (Estimated)
RAPT Rapt Therapeutics	-$129.87M	-$19.20	N/A	N/A	N/A	N/A	-81.47%	-70.24%	8/6/2025 (Estimated)

Latest ANVS, ALXO, RAPT, and MDWD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ALXO ALX Oncology	-$0.46	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	RAPT Rapt Therapeutics	-$0.68	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	ANVS Annovis Bio	-$0.36	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	MDWD MediWound	-$0.55	N/A	N/A	N/A	$5.68 million	N/A
5/21/2025	Q1 2025	MDWD MediWound	-$0.65	-$0.07	+$0.58	-$0.07	$5.20 million	$3.96 million
5/13/2025	Q1 2025	ANVS Annovis Bio	-$0.47	-$0.32	+$0.15	-$0.32	N/A	N/A
5/8/2025	Q1 2025	ALXO ALX Oncology	-$0.47	-$0.58	-$0.11	-$0.58	N/A	N/A
5/8/2025	Q1 2025	RAPT Rapt Therapeutics	-$2.48	-$0.64	+$1.84	-$0.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALXO ALX Oncology	0.09	5.47	5.47
ANVS Annovis Bio	N/A	10.68	10.68
MDWD MediWound	N/A	2.15	1.99
RAPT Rapt Therapeutics	N/A	21.11	21.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALXO ALX Oncology	97.97%
ANVS Annovis Bio	15.83%
MDWD MediWound	46.83%
RAPT Rapt Therapeutics	99.09%

Insider Ownership

Company	Insider Ownership
ALXO ALX Oncology	21.00%
ANVS Annovis Bio	20.80%
MDWD MediWound	9.20%
RAPT Rapt Therapeutics	2.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALXO ALX Oncology	40	53.40 million	42.18 million	Optionable
ANVS Annovis Bio	3	19.49 million	15.43 million	Optionable
MDWD MediWound	80	10.81 million	9.81 million	Optionable
RAPT Rapt Therapeutics	80	16.54 million	16.15 million	Optionable

ANVS, ALXO, RAPT, and MDWD Headlines

Recent News About These Companies

Wall Street Analysts Believe Rapt Therapeutics (RAPT) Could Rally 122.22%: Here's is How to Trade

August 1 at 10:56 AM | zacks.com

Rapt Therapeutics (NASDAQ:RAPT) Upgraded to Neutral at JPMorgan Chase & Co.

August 1 at 2:16 AM | americanbankingnews.com

Rapt Therapeutics (NASDAQ:RAPT) Upgraded by JPMorgan Chase & Co. to "Neutral" Rating

July 31 at 7:33 AM | marketbeat.com

RAPT Therapeutics Unveils Plans for RPT904 Development

July 30 at 11:42 PM | theglobeandmail.com

Rapt Therapeutics upgraded to Neutral from Underweight at JPMorgan

July 30 at 11:42 PM | msn.com

JP Morgan Upgrades RAPT Therapeutics (RAPT)

July 30 at 11:42 PM | msn.com

Rapt Therapeutics (NASDAQ:RAPT) Upgraded at Wall Street Zen

July 28, 2025 | americanbankingnews.com

What is Lifesci Capital's Estimate for RAPT Q2 Earnings?

July 27, 2025 | americanbankingnews.com

Rapt Therapeutics (NASDAQ:RAPT) Raised to Hold at Wall Street Zen

July 26, 2025 | marketbeat.com

Q2 Earnings Forecast for RAPT Issued By Lifesci Capital

July 25, 2025 | marketbeat.com

Lifesci Capital Upgrades Rapt Therapeutics (NASDAQ:RAPT) to Strong-Buy

July 25, 2025 | americanbankingnews.com

LifeSci Capital Initiates Coverage of RAPT Therapeutics (RAPT) with Outperform Recommendation

July 23, 2025 | msn.com

Rapt Therapeutics (NASDAQ:RAPT) Coverage Initiated by Analysts at Lifesci Capital

July 23, 2025 | marketbeat.com

Rapt Therapeutics initiated with an Outperform at LifeSci Capital

July 23, 2025 | msn.com

Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Recommendation of "Hold" from Brokerages

July 23, 2025 | americanbankingnews.com

Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Rating of "Hold" from Analysts

July 23, 2025 | marketbeat.com

Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why

July 15, 2025 | msn.com

Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why

July 15, 2025 | zacks.com

Aegle Therapeutics Names Industry Veteran Scott Braunstein, M.D. as Chairman of the Board

July 15, 2025 | tmcnet.com

Best Momentum Stocks to Buy for July 15th

July 15, 2025 | zacks.com

Does Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect?

July 15, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS, ALXO, RAPT, and MDWD Company Descriptions

ALX Oncology NASDAQ:ALXO

$0.52 -0.05 (-8.70%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$0.53 +0.01 (+1.91%)

As of 08/1/2025 05:31 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Annovis Bio NYSE:ANVS

$2.51 -0.22 (-8.06%)

Closing price 08/1/2025 03:59 PM Eastern

Extended Trading

$2.54 +0.03 (+1.24%)

As of 08/1/2025 06:30 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

MediWound NASDAQ:MDWD

$18.53 -0.11 (-0.59%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$18.53 0.00 (0.00%)

As of 08/1/2025 04:04 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Rapt Therapeutics NASDAQ:RAPT

$10.49 -0.31 (-2.87%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$10.52 +0.03 (+0.24%)

As of 08/1/2025 07:04 PM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time